Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors.Yeung, K.S., Beno, B.R., Mosure, K., Zhu, J., Grant-Young, K.A., Parcella, K., Anjanappa, P., Bora, R.O., Selvakumar, K., Wang, Y.K., Fang, H., Krause, R., Rigat, K., Liu, M., Lemm, J., Sheriff, S., Witmer, M., Tredup, J., Jardel, A., Kish, K., Parker, D., Haskell, R., Santone, K., Meanwell, N.A., Soars, M.G., Roberts, S.B., Kadow, J.F.
(2018) ACS Med Chem Lett 9: 1217-1222
- PubMed: 30613329
- DOI: https://doi.org/10.1021/acsmedchemlett.8b00379
- Primary Citation of Related Structures:
- PubMed Abstract:
In solving the P-gp and BCRP transporter-mediated efflux issue in a series of benzofuran-derived pan-genotypic palm site inhibitors of the hepatitis C virus NS5B replicase, it was found that close attention to physicochemical properties was essential. In these compounds, where both molecular weight (MW >579) and TPSA (>110 Å 2 ) were high, attenuation of polar surface area together with weakening of hydrogen bond acceptor strength of the molecule provided a higher intrinsic membrane permeability and more desirable Caco-2 parameters, as demonstrated by trifluoroacetamide 11 and the benchmark N -ethylamino analog 12 . In addition, the tendency of these inhibitors to form intramolecular hydrogen bonds potentially contributes favorably to the improved membrane permeability and absorption. The functional group minimization that resolved the efflux problem simultaneously maintained potent inhibitory activity toward a gt-2 HCV replicon due to a switching of the role of substituents in interacting with the Gln414 binding pocket, as observed in gt-2a NS5B/inhibitor complex cocrystal structures, thus increasing the efficiency of the optimization. Noteworthy, a novel intermolecular S=O···C=O n → π* type interaction between the ligand sulfonamide oxygen atom and the carbonyl moiety of the side chain of Gln414 was observed. The insights from these structure-property studies and crystallography information provided a direction for optimization in a campaign to identify second generation pan-genotypic NS5B inhibitors.
Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States.